CVS Health Corporation

NYSE:CVS Lagerbericht

Marktkapitalisierung: US$75.7b

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

CVS Health Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

CVS Health wird ein jährliches Gewinn- und Umsatzwachstum von 8.5% bzw. 4.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12% betragen.

Wichtige Informationen

8.8%

Wachstumsrate der Gewinne

10.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum17.1%
Wachstumsrate der Einnahmen4.7%
Zukünftige Eigenkapitalrendite11.8%
Analystenabdeckung

Good

Zuletzt aktualisiert04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 03
CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

The Correct Play On CVS Health

Jun 06

CVS Health: Downside Movement Is Overdramatic

May 26

CVS Health: Secure Dividend And Upside Potential Presents Compelling Opportunity

May 15

We Think Shareholders Are Less Likely To Approve A Pay Rise For CVS Health Corporation's (NYSE:CVS) CEO For Now

May 10
We Think Shareholders Are Less Likely To Approve A Pay Rise For CVS Health Corporation's (NYSE:CVS) CEO For Now

CVS Health: A Terrible Earnings Report, But An Undervalued Stock

May 04

CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 03
CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

CVS Health: 8x P/E, 8% Growth Projection - It's A Market Blind Spot

Apr 22

Sentiment Still Eluding CVS Health Corporation (NYSE:CVS)

Apr 14
Sentiment Still Eluding CVS Health Corporation (NYSE:CVS)

CVS Health: Lookback, Management Guidance Vs. Results 2018-To-Date

Apr 10

Does CVS Health (NYSE:CVS) Have A Healthy Balance Sheet?

Mar 27
Does CVS Health (NYSE:CVS) Have A Healthy Balance Sheet?

CVS Health: Better Times Likely Ahead

Mar 12

CVS Health: Lower Guidance But Risk/Reward Remains Attractive

Feb 15

CVS Health FY23 Earnings: Downgrades Inevitable, Long Term Outlook In The Balance

Feb 07

CVS Health: Back In The Buy Column

Jan 21

CVS Health (NYSE:CVS) Has Announced That It Will Be Increasing Its Dividend To $0.665

Jan 17
CVS Health (NYSE:CVS) Has Announced That It Will Be Increasing Its Dividend To $0.665

CVS Health: Shares Remain Modestly Undervalued, Robust Free Cash Flow, Technical Strength

Jan 08

CVS Health (NYSE:CVS) Is Paying Out A Larger Dividend Than Last Year

Jan 03
CVS Health (NYSE:CVS) Is Paying Out A Larger Dividend Than Last Year

CVS Health: Risk/Reward Highly Skewed To The Upside

Dec 15

CVS Health (NYSE:CVS) Is Increasing Its Dividend To $0.665

Dec 13
CVS Health (NYSE:CVS) Is Increasing Its Dividend To $0.665

We Think CVS Health (NYSE:CVS) Is Taking Some Risk With Its Debt

Dec 08
We Think CVS Health (NYSE:CVS) Is Taking Some Risk With Its Debt

CVS Health: A Good Fit To Buffett's 10x Pretax Rule

Dec 07

CVS Health: Not One Dividend Cut In 30 Years And A Good Upside

Nov 27

CVS Health: All Eyes On December Investor Day

Nov 21

CVS Health Ahead Of Q3 Earnings: Making The Pivot Toward Value-Based Care Work

Oct 26

CVS Health: 'Only' A Fair Company For A Wonderful Price?

Oct 20

CVS Health Offers Recession-Resistant Growth With Transformation

Oct 05

CVS Stock: The Risk-Reward Is In A Better Place

Sep 18

Gewinn- und Umsatzwachstumsprognosen

NYSE:CVS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2026410,28410,03811,39314,56315
12/31/2025387,0948,69010,11812,98924
12/31/2024369,6287,3829,23711,88820
3/31/2024359,6627,3218,13910,891N/A
12/31/2023356,6238,34410,39513,426N/A
9/30/2023346,6018,63211,30214,110N/A
6/30/2023338,0722,96517,67420,517N/A
3/31/2023329,9154,09317,39220,052N/A
12/31/2022321,6294,31113,45016,177N/A
9/30/2022314,3433,28319,49822,134N/A
6/30/2022306,9338,28715,86818,532N/A
3/31/2022298,7708,04116,19418,936N/A
12/31/2021290,9128,00115,74518,265N/A
9/30/2021283,9817,58615,19117,827N/A
6/30/2021277,2857,21211,61814,180N/A
3/31/2021270,1157,40412,92815,452N/A
12/31/2020267,9087,18813,42815,865N/A
9/30/2020265,2857,95112,64114,932N/A
6/30/2020262,9808,25713,62815,986N/A
3/31/2020260,9617,21711,72214,205N/A
12/31/2019255,7656,62910,39112,848N/A
9/30/2019243,3314,46410,21812,693N/A
6/30/2019226,0534,3248,44810,862N/A
3/31/2019209,623-1746,1878,458N/A
12/31/2018193,919-5976,8288,865N/A
9/30/2018188,0553,0984,2926,250N/A
6/30/2018186,9672,9895,8227,764N/A
3/31/2018185,9446,6454,8866,829N/A
12/31/2017184,7656,606N/A8,007N/A
9/30/2017182,3515,029N/A10,264N/A
6/30/2017180,7855,281N/A11,587N/A
3/31/2017178,8255,108N/A11,235N/A
12/31/2016177,5265,291N/A10,141N/A
9/30/2016172,7015,084N/A11,591N/A
6/30/2016166,7294,781N/A9,477N/A
3/31/2016160,1735,126N/A8,867N/A
12/31/2015153,2905,202N/A8,539N/A
9/30/2015149,1995,027N/A8,264N/A
6/30/2015145,5774,741N/A8,089N/A
3/31/2015143,0104,713N/A7,949N/A
12/31/2014139,3674,626N/A8,137N/A
9/30/2014135,1424,576N/A6,252N/A
6/30/2014132,0534,887N/A6,310N/A
3/31/2014128,6994,775N/A6,315N/A
12/31/2013126,7614,600N/A5,783N/A
9/30/2013125,3124,450N/A5,976N/A
6/30/2013123,6074,206N/A5,196N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CVSDas prognostizierte Gewinnwachstum (8.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: CVSDie Erträge des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: CVSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CVSDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: CVSDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CVSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12 %).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y